Core Viewpoint - Varex Imaging is experiencing stable demand despite geopolitical events and tariff volatility, with expectations for incremental margin improvement as prior tariff costs roll through inventory and long-term growth initiatives tied to manufacturing expansion in India and advancements in technology [6][12][18] Group 1: Demand and Market Conditions - Current conditions are described as "directionally positive," with ongoing policy discussions potentially leading to further changes [1] - Demand trends in security applications are at least "flat to positive," with increased inquiries about Varex's technologies [3] - The healthcare sector remains the largest end-market for Varex, driven by patient dynamics rather than macroeconomic events, with no significant impacts on hospital capital budgets reported [4] Group 2: Tariff and Pricing Adjustments - Varex has adjusted pricing and pass-through mechanisms in response to tariff escalations, with inventory levels affected by higher-tariff inventory still on hand [2] - If the current tariff regime remains, gross margin could improve modestly as older, higher-tariff inventory is cleared, with an estimated benefit of 30 to 50 basis points [7] Group 3: Regional Insights - In China, demand is stable to slightly growing, with a shift towards a more mature replacement-driven market, supported by government initiatives to enhance healthcare delivery in rural areas [8][9] - Domestic Chinese imaging players are gaining market share in competitive tenders, which is favorable for Varex as it supplies many of these players [10] Group 4: Growth Initiatives - Varex is ramping up production at two facilities in India, with expectations of generating approximately $100 million in incremental radiographic revenue over two years starting from fiscal 2027 [12][13] - The company is focused on photon-counting CT technology, aiming for deeper engagement with multiple OEMs by 2028 [14] Group 5: Financial Performance and Strategy - Recent debt refinancing has reduced coupon rates by about 175 basis points, resulting in annual interest savings of approximately $7 million to $8 million, translating to an annualized EPS benefit of about $0.15 to $0.16 [15] - The company aims to move corporate gross margin toward the high 30% range over the next few years, driven by growth in photon counting, cargo inspection systems, and India radiographic growth [18]

Core Insights - Varex Imaging reported a strong start to fiscal 2026, with first-quarter results at the high end of guidance, driven by growth in industrial markets and stable medical performance [4][3] Financial Performance - On a GAAP basis, gross margin was 33%, operating income was $15 million, net income was $2 million, and GAAP EPS was $0.05 per diluted share [1] - Non-GAAP gross margin was 34%, with non-GAAP EBITDA of $29 million, up 12% year over year, and non-GAAP EPS of $0.19, an increase from $0.10 in the previous year [2] - Total revenue for the first quarter was $210 million, reflecting a 5% year-over-year increase, with industrial segment revenue rising 17% [3][6] Revenue Breakdown - Medical revenue accounted for $145 million (69% of total revenue), while industrial revenue was $65 million (31% of total revenue) [1] - Regionally, the Americas grew by 17%, EMEA rose by 7%, and APAC declined by 7% year over year [1] Industrial Segment Insights - The industrial segment's growth was attributed to demand in cargo security systems and non-destructive testing (NDT) [11][12] - Management noted that orders in the industrial segment are "tender-driven" and can be lumpy, with potential for double-digit growth contingent on wins and shipment timing [12] Medical Segment Insights - The medical segment showed stable performance, with strong demand for X-ray sources, particularly in high-end CT, and increasing customer engagement on next-generation system designs [7][8] - Mammography exceeded sales trends, while CT, fluoroscopy, and radiography were in line with sales trends [10] Balance Sheet and Cash Flow - Inventory increased by $29 million to $328 million, leading to a $16 million operating cash outflow [5][15] - Varex ended the quarter with $126 million in cash and gross debt of $370 million, with a net leverage of approximately 1.9x [16] Future Outlook - For the second quarter, Varex guided revenue between $210 million and $225 million, with non-GAAP EPS expected to be between $0.15 and $0.25 [18] - Management expressed confidence in customer engagement across both segments, highlighting innovation in medical imaging and expanding industrial applications [17]